IMCR IMMUNOCORE HLDGS PLC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNOCORE HLDGS PLC reported revenue of $116M (up 18.3% from a year earlier), net income of −$808K and diluted EPS of −$0.02; over the last four quarters revenue was $431M and net income −$18.1M; for the fiscal year ended December 2025 revenue was $400M, up 29.0% on the year before.
IMCR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $400M, gross profit n/a, operating income −$45.4M, net income −$35.5M (margin -8.9%), EPS −$0.71
- Fiscal year ended Dec 2024: revenue $310M, gross profit n/a, operating income −$70.5M, net income −$51.1M (margin -16.5%), EPS −$1.02
- Fiscal year ended Dec 2023: revenue $249M, gross profit n/a, operating income −$59.6M, net income −$55.3M (margin -22.2%), EPS −$1.13
- Fiscal year ended Dec 2022: revenue $174M, gross profit n/a, operating income −$51.7M, net income −$52.5M (margin -30.1%), EPS −$1.15
- Fiscal year ended Dec 2021: revenue $36.5M, gross profit n/a, operating income −$175M, net income −$180M (margin -493.4%), EPS −$4.24
IMCR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $116M (up 18.3% year over year), net income −$808K, EPS −$0.02
- Quarter ended Mar 31, 2026: revenue $107M (up 13.6% year over year), net income $13.0M, EPS $0.25
- Quarter ended Dec 31, 2025 (from the annual report): revenue $104M (up 24.3% year over year), net income −$30.1M, EPS −$0.61
- Quarter ended Sep 30, 2025: revenue $104M (up 29.2% year over year), net income −$177K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue $98.0M (up 29.9% year over year), net income −$10.3M, EPS −$0.20
- Quarter ended Mar 31, 2025: revenue $93.9M (up 33.2% year over year), net income $5.02M, EPS $0.10
- Quarter ended Dec 31, 2024 (from the annual report): revenue $84.1M (up 19.8% year over year), net income −$23.8M, EPS −$0.47
- Quarter ended Sep 30, 2024: revenue $80.2M (up 23.7% year over year), net income $8.74M, EPS $0.17
- Quarter ended Jun 30, 2024: revenue $75.4M (up 26.2% year over year), net income −$11.6M, EPS −$0.23
- Quarter ended Mar 31, 2024: revenue $70.5M (up 29.0% year over year), net income −$24.4M, EPS −$0.49
- Quarter ended Dec 31, 2023 (from the annual report): revenue $70.2M, net income −$19.7M, EPS −$0.40
- Quarter ended Sep 30, 2023: revenue $64.9M, net income $906K, EPS $0.02
- Quarter ended Jun 30, 2023: revenue $59.8M, net income −$17.0M, EPS −$0.35
- Quarter ended Mar 31, 2023: revenue $54.7M, net income −$19.4M, EPS −$0.40
IMCR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$10.7M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow $26.1M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow $2.94M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$49.2M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$143M, share buybacks n/a
IMCR balance sheet
- Jun 30, 2026: cash $485M, total assets $1.12B, total liabilities $700M, shareholders' equity $420M
- Mar 31, 2026: cash $453M, total assets $1.07B, total liabilities $678M, shareholders' equity $394M
- Dec 31, 2025: cash $468M, total assets $1.07B, total liabilities $686M, shareholders' equity $381M
- Sep 30, 2025: cash $498M, total assets $1.10B, total liabilities $706M, shareholders' equity $397M
- Jun 30, 2025: cash $488M, total assets $1.08B, total liabilities $694M, shareholders' equity $388M
- Mar 31, 2025: cash $477M, total assets $1.03B, total liabilities $650M, shareholders' equity $378M
- Dec 31, 2024: cash $456M, total assets $1.01B, total liabilities $649M, shareholders' equity $361M
- Sep 30, 2024: cash $538M, total assets $1.08B, total liabilities $707M, shareholders' equity $378M
What is IMCR's revenue?
IMMUNOCORE HLDGS PLC reported $431M of revenue over its last four quarters, through June 30, 2026.
Is IMCR profitable?
No. IMMUNOCORE HLDGS PLC lost $18.1M over the last four quarters.
What is IMCR's EPS?
Diluted earnings per share over the last four quarters were −$0.38; −$0.02 in the latest quarter.